BDSX vs. AIRS, TOI, EUDA, DCGO, CORBF, XGN, QIPT, SERA, BMGL, and ATPC
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include AirSculpt Technologies (AIRS), Oncology Institute (TOI), EUDA Health (EUDA), DocGo (DCGO), Global Cord Blood (CORBF), Exagen (XGN), Quipt Home Medical (QIPT), Sera Prognostics (SERA), Basel Medical Group (BMGL), and Agape ATP (ATPC). These companies are all part of the "healthcare" industry.
Biodesix vs.
Biodesix (NASDAQ:BDSX) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, community ranking, media sentiment, analyst recommendations, profitability and dividends.
Biodesix presently has a consensus target price of $1.75, suggesting a potential upside of 342.93%. AirSculpt Technologies has a consensus target price of $3.75, suggesting a potential downside of 4.34%. Given Biodesix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biodesix is more favorable than AirSculpt Technologies.
In the previous week, Biodesix had 10 more articles in the media than AirSculpt Technologies. MarketBeat recorded 10 mentions for Biodesix and 0 mentions for AirSculpt Technologies. AirSculpt Technologies' average media sentiment score of 0.00 beat Biodesix's score of -0.39 indicating that AirSculpt Technologies is being referred to more favorably in the news media.
AirSculpt Technologies has higher revenue and earnings than Biodesix. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.
AirSculpt Technologies has a net margin of -4.13% compared to Biodesix's net margin of -66.84%. AirSculpt Technologies' return on equity of 2.22% beat Biodesix's return on equity.
Biodesix has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, AirSculpt Technologies has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.
Biodesix received 24 more outperform votes than AirSculpt Technologies when rated by MarketBeat users. Likewise, 76.09% of users gave Biodesix an outperform vote while only 35.48% of users gave AirSculpt Technologies an outperform vote.
21.0% of Biodesix shares are owned by institutional investors. Comparatively, 91.5% of AirSculpt Technologies shares are owned by institutional investors. 69.2% of Biodesix shares are owned by company insiders. Comparatively, 76.6% of AirSculpt Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
AirSculpt Technologies beats Biodesix on 10 of the 18 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
This page (NASDAQ:BDSX) was last updated on 5/21/2025 by MarketBeat.com Staff
